secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001193125-23-137689
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia Q1 net loss $26.2M; Auryxia revenue $34.8M; vadadustat approved in 32 countries
--------------------------------------------------------------------------------

- Net loss of $26.2M improved from $62.4M in Q1 2022; total revenue $40.1M vs $61.7M.
- Auryxia net product revenue $34.8M, down 15.9% YoY; company reaffirms 2023 guidance $175-180M.
- European Commission approved Vafseo (vadadustat) for anemia in CKD dialysis patients; approved in 32 countries.
- Expects FDA Formal Dispute Resolution response within next 30 days; positive alternative dosing study results.
- Cash $57.0M; expects to fund operations for at least 12 months with cash and Auryxia revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000119312523137689/0001193125-23-137689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000119312523137689/d439043d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-137689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer